Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,545,884 protect, and when does it expire?

Patent ► Subscribe protects GILOTRIF and is included in one NDA. There has been one Paragraph IV challenge on Gilotrif.

This patent has thirty-two patent family members in thirty-two countries.

Summary for Patent: ► Subscribe

Title:Solid pharmaceutical formulations comprising BIBW 2992
Abstract: The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA.sub.2) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA.sub.2, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.
Inventor(s): Messerschmid; Roman (Biberach, DE), Friedl; Thomas (Ochsenhausen, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/995,715
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
afatinib dimaleate
TABLET;ORAL201292-001Jul 12, 2013RXYesNo► Subscribe► SubscribeY
Boehringer Ingelheim
afatinib dimaleate
TABLET;ORAL201292-002Jul 12, 2013RXYesNo► Subscribe► SubscribeY
Boehringer Ingelheim
afatinib dimaleate
TABLET;ORAL201292-003Jul 12, 2013RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08157800Jun 6, 2008
09160297May 14, 2009
PCT Information
PCT FiledJune 05, 2009PCT Application Number:PCT/EP2009/056944
PCT Publication Date:December 10, 2009PCT Publication Number: WO2009/147238

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Eurasian Patent Organization201001852► Subscribe
Eurasian Patent Organization022168► Subscribe
EcuadorSP10010650► Subscribe
European Patent Office2299971► Subscribe
Hong Kong1152478► Subscribe
CroatiaP20161061► Subscribe
Spain2588031► Subscribe
HungaryE029863► Subscribe
Israel209054► Subscribe
Japan2011522011► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
US Army
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus